Hexarelin
Hexarelin
Regulatory Status
Included in the PeptideUnicorn FDA reclassification tracker as under review.
FDA · Updated May 2026
Generally treated as research-only outside licensed channels.
MHRA · Updated May 2026
Not listed in the public tracker dataset; supply claims require case-by-case review.
TGA · Updated May 2026
Growth-hormone secretagogues are prohibited for athletes subject to anti-doping rules.
WADA · Updated May 2026
Overview
Hexarelin is a synthetic growth hormone secretagogue discussed in endocrine, recovery, and body-composition research. PeptideUnicorn currently treats this as a stub profile while the editorial team expands the evidence summary, legal status notes, and citations.
Regulatory Context
Hexarelin is included in the 2026 FDA peptide reclassification tracker as under review. This page is educational only and should not be interpreted as medical, legal, or sourcing advice.
Continue Reading
Readers also explore
GHRP-2
Growth Hormone Releasing Peptide-2
Growth hormone signaling · Body composition research
Open profileGHRP-6
Growth Hormone Releasing Peptide-6
Growth hormone signaling · Appetite research
Open profileIpamorelin
Ipamorelin Acetate
growth hormone release · muscle growth · fat loss
Open profileState of Peptides 2026
Get the free report and peptide profile updates.
Evidence notes, regulatory changes, and practical research guides in your inbox. Education only - not medical advice.
Get the PeptideUnicorn update
New profiles, regulatory changes, practical guides, and vendor review notes delivered to your inbox.
Get our free State of Peptides 2026 report when you subscribe.